duchenne Ireland - Fundraising

By: Duchenne Ireland  05/12/2011
Keywords: charity, Clinical Trials, Research Projects

Octob er 2nd 2010 - Ireland

Duchenne Ireland Charity Funds Cutting Edge Personalised Research

Duchenne Ireland issues a call for funding applications each year and there is considerable interest from research groups at home and abroad in obtaining financial assistance to perform much needed translational research into Duchenne Muscular Dystrophy. Decisions are made quickly by the charity’s research committee following peer review by international experts to ensure that important work can proceed without unnecessary delay. The charity, in it’s first grant call, contributed more than €200,000 to research projects that offer hope of promising breakthroughs in terms of treatments for this generation of boys.

Since it was set up a few short years ago, Duchenne Ireland has been involved in funding projects in Europe and elsewhere and it is hoped that such involvement can be continued. This will be possible only through additional fund-raising efforts which will help to ensure that money will be available to keep these important project going. The types and nature of the projects are very varied but in all cases the emphasis is on translational research that could have short or mid-term impact.

The latest round of funding has seen Duchenne Ireland commit another €180,000 towards a project that hopes to deliver results using a technique called exon skipping to overcome some of the negative effects of Duchenne Muscular Dystrophy. The project aims to identify the potential of exon skipping therapy for boys with Duchenne at a personalised level.

Numerous clinical trials are underway internationally for Duchenne therapies and Irish boys with Duchenne are currently missing out on the potential of these trials including upcoming “exon skipping” trials due to the lack of a clinical trial centre for Duchenne in Ireland. Ireland at present is one of the only countries in Europe that does not have a Duchenne Clinical Trial Centre. Duchenne Ireland is actively working with the Government and national Clinicians on a proposal to establish such a clinical trial centre for Duchenne in Ireland.

Funding for Duchenne Ireland research is generated from charity events such as this weekend’s (Saturday Oct 2nd) Tour Duchenne 2010, taking place at 9am at the Aquarium, Strand Road, Bray.
Tour Duchenne Is Duchenne Ireland’s annual charity cycle to raise funds for Duchenne Muscular Dystrophy research. Each year cyclists get ready for a super cycle route within Ireland. This year it takes them on the “Beach Tour” from Bray Seafront to Brittas Bay and back (approx 85 km.

About Duchenne

Duchenne is the most common fatal genetic disorder diagnosed during early childhood, affecting approximately 1 out of every 3,500 boys and 20,000 babies born each year. Duchenne causes loss of muscle function and independence. There is currently no cure for Duchenne, but much research is currently underway to find an interim therapy that will help delay the progression of the disease until a cure is found.

66% of all duchenne cases are inherited from the boys mother. 33% of Duchenne cases diagnosed are not inherited but cause by environmental factors. This means that any boy can be diagnosed with Duchenne. Boys are usually only diagnosed between the ages of 3 and 5 years of age.Current research is working on replacing the missing dystrophin in children with Duchenne. Clinical trials are already underway, but we need more direct funding to this research to ensure it progresses faster than the disease.

About Duchenne Ireland

Duchenne Ireland is a patient organization and registered Irish Charity (CHY 18197) established to facilitate funding translational research into Duchenne Muscular Dystrophy. Duchenne Ireland is affiliated with numerous patient groups and clinical, research and support networks for Duchenne Muscular Dystrophy. Duchenne Ireland works internationally to rapidly advance research into Duchenne and welcomes organization, parents and supporter who believe they can help to forward progress in this research.

The aims of Duchenne Ireland is to raise awareness of Duchenne Muscular Dystrophy at local, national and government level. Our objective is to raise funds which shall go directly to the researchers and clinicians who we believe have the best chance of developing improved therapies which will benefit this generation. We are also working towards achieving an infrastructure which is on a par with best international practice.

The information in this article was current at 02 Dec 2011

Keywords: charity, Clinical Trial, Clinical Trials, Duchenne Muscular Dystrophy, Muscular Dystrophy, Research Projects

Contact Duchenne Ireland


Print this page


Other products and services from Duchenne Ireland


duchenne Ireland - News

Three patients, one each in the 2.0, 10 and 20 mg/kg cohorts, demonstrated substantial generation of new dystrophin-positive muscle fibers, including the first ever reported generation of dystrophin-positive muscle fibers of more than 50% of normal in a patient following systemic administration of a drug.


duchenne Ireland - Research

Safety study follow-on clinical study for patients who participated in earlier ataluren. If you have any questions relating to this announcement or the follow-on safety study. As reported in our June Programme Update, Genzyme has been actively exploring. Ataluren and as part of our ongoing commitment in keeping the DBMD community. Transition of all DBMD related activities to PTC. PTC for the ataluren nmDBMD programme.


duchenne Ireland - Events

The cycle arranged to fund research into Duchenne Muscular Dystrophy will take the participants from the National University of Ireland in Galway to Maynooth. Cyclists accross Ireland are getting ready for the inaugural "Tour Duchenne" charity cycling event on Saturday 12th and Sunday 13th of September 2009. Be on the look out for our yellow "Tour Duchenne 2009" cycling jerseys.


duchenne Ireland - Collaboration

This project would not be in place at all if it was not for the dedicated work of Professor Steve Wilton and Professor Sue Fletcher from the University of Western Australia who have consistently progressed therapies for Duchenne boys over the past number of years since Exon Skipping showed initial therapeutic potential.